Irritable Bowel Syndrome Treatment Market to Reach $2.01 Billion by 2026 at 8.2% CAGR

27 Aug 2021
www.biospace.com
Expansion in geriatric populace, ascend in the pervasiveness of gastrointestinal problems, and flood in the quantity of pipeline drugs have supported the development of the worldwide touchy irritable bowel syndrome treatment market Allied Market Research as of late distributed a report, named, "Irritable bowel syndrome treatment Market by Type (IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), and Mixed (IBS-M), Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, and Others), and End User (Hospitals Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2019–2026". As per the report, the worldwide irritable bowel syndrome treatment industry was fixed at $1.07 billion out of 2018 and is relied upon to reach $2.01 billion by 2026, enrolling a CAGR of 8.2% from 2019 to 2026. Motivators for market development Expansion in geriatric populace, ascend in the pervasiveness of gastrointestinal problems, and flood in the quantity of pipeline drugs have supported the development of the worldwide touchy irritable bowel syndrome treatment market. Nonetheless, helpless interest from immature nations hampers the market development. In actuality, undiscovered potential in the creating economies is relied upon to set out worthwhile open doors soon. Request Sample Report at: The rifaximin section ruled the market Result, the Rifaximin portion held the biggest offer in 2018, represented more than 33% of the worldwide peevish gut condition treatment market. In addition, the fragment is relied upon to enlist the biggest CAGR of 9.4% during the gauge time frame, because of expanded interest to treat IBS with Diarrhea (IBS-D) brought about by Escherichia coli (E. coli) microscopic organisms in grown-ups and kids. The report incorporates an examination of different sections like Eluxadoline, Lubiprostone, Linaclotide, and others. The online drug stores section to show the quickest CAGR through 2026 The online drug stores section is expected to enroll the quickest CAGR of 9.9% from 2019 to 2026, attributable to ascend in inclination for web based buying of medications over the conventional techniques, flood in mindfulness with respect to online drug stores, and expansion in the quantity of Internet clients. Notwithstanding, the pharmacies and retail drug stores section held the biggest offer in 2018, representing the greater part of the worldwide crabby gut condition treatment market, because of solid presence of retail drug stores all throughout the planet and the accommodation offered by them. North America held the overwhelming majority The worldwide peevish entrail condition therapy market across North America held the biggest offer in 2018, representing almost 50% of the market, attributable to ascend in gastrointestinal sicknesses like stomach torment, loose bowels, and obstruction and presence of cutting edge medical care offices with prepared clinical experts. Nonetheless, the market across the Asia-Pacific locale is projected to enlist the quickest CAGR of 9.9% during the estimate time frame. This is because of progress in medical services foundation, ascend in the quantity of emergency clinics furnished with cutting edge clinical offices, presence of the creating R&D area, and expansion in medical care changes. Major market players Abbott Laboratories Ardelyx Inc. Allergan plc AstraZeneca plc Astellas Pharma Inc. Johnson & Johnson (McNeil Consumer Healthcare) GlaxoSmithKline Plc Sebela Pharmaceuticals Inc. Novartis AG Takeda Pharmaceutical Company Ltd. We have also published few syndicated market studies in the other trending area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market. Trending Reports: U.S. Thrombectomy Devices Market: Opportunity Analysis and Industry Forecast, 2018 - 2025 U.S. Biliary Stents Market: Opportunity Analysis and Industry Forecast, 2018 – 2025 About Us Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. Contact: David Correa 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022 UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-20-66346060 Fax: +1(855)550-5975 help@alliedmarketresearch (dot) com
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.